PURPOSE: African American women are more likely to be diagnosed with metastatic breast cancer at the time of presentation than whites, and have shorter survival once diagnosed. This study examines racial differences in clinical outcomes in the setting of two large cooperative group randomized clinical trials. PATIENTS AND METHODS: The study cohort consisted of 787 white (80%) and 195 African American (20%) patients with metastatic breast cancer enrolled in two successive Cancer and Leukemia Group B (CALGB) trials using taxanes in the metastatic setting. Differences in overall survival (OS), response incidence, and time to treatment failure (TTF) were examined by race. In addition, differences in the incidence of baseline and treatment-related toxicities were examined. RESULTS: With 779 deaths (166 African Americans and 613 whites), median OS was 14.3 months for African Americans and 18.75 months for whites (hazard ratio [HR] = 1.37; 95% CI, 1.15 to 1.63). When adjusted for prognostic factors, African Americans had a 24% increase in the hazard of death compared with whites (HR = 1.24; 95% CI, 1.02 to 1.51). No significant differences in TTF or overall response to therapy were seen. No clinically significant toxicity differences were seen. CONCLUSION: African Americans with metastatic breast cancer have an increased hazard of death compared with whites despite the receipt of similar per-protocol treatment, but experience no differences in TTF or overall response to therapy. We hypothesize that more direct and robust measures of comorbidities, and perhaps other factors such as receipt of subsequent therapy could help further explain the observed survival difference.
PURPOSE: African American women are more likely to be diagnosed with metastatic breast cancer at the time of presentation than whites, and have shorter survival once diagnosed. This study examines racial differences in clinical outcomes in the setting of two large cooperative group randomized clinical trials. PATIENTS AND METHODS: The study cohort consisted of 787 white (80%) and 195 African American (20%) patients with metastatic breast cancer enrolled in two successive Cancer and Leukemia Group B (CALGB) trials using taxanes in the metastatic setting. Differences in overall survival (OS), response incidence, and time to treatment failure (TTF) were examined by race. In addition, differences in the incidence of baseline and treatment-related toxicities were examined. RESULTS: With 779 deaths (166 African Americans and 613 whites), median OS was 14.3 months for African Americans and 18.75 months for whites (hazard ratio [HR] = 1.37; 95% CI, 1.15 to 1.63). When adjusted for prognostic factors, African Americans had a 24% increase in the hazard of death compared with whites (HR = 1.24; 95% CI, 1.02 to 1.51). No significant differences in TTF or overall response to therapy were seen. No clinically significant toxicity differences were seen. CONCLUSION: African Americans with metastatic breast cancer have an increased hazard of death compared with whites despite the receipt of similar per-protocol treatment, but experience no differences in TTF or overall response to therapy. We hypothesize that more direct and robust measures of comorbidities, and perhaps other factors such as receipt of subsequent therapy could help further explain the observed survival difference.
Authors: Charlotte Jones-Burton; Stephen L Seliger; Jeanine Brown; Lucy Stackiewicz; Van Doren Hsu; Jeffrey C Fink Journal: Nephrol Dial Transplant Date: 2005-09-27 Impact factor: 5.992
Authors: James J Dignam; Kelly Wieand; Karen A Johnson; Peter Raich; Stewart J Anderson; Carol Somkin; D Lawrence Wickerham Journal: Breast Cancer Res Treat Date: 2005-12-06 Impact factor: 4.872
Authors: Peggy L Porter; Mary Jo Lund; Ming Gang Lin; Xiaopu Yuan; Jonathan M Liff; Elaine W Flagg; Ralph J Coates; J William Eley Journal: Cancer Date: 2004-06-15 Impact factor: 6.860
Authors: Lyndsay N Harris; Gloria Broadwater; Nancy U Lin; Alexander Miron; Stuart J Schnitt; David Cowan; Jonathan Lara; Ira Bleiweiss; Donald Berry; Matthew Ellis; Daniel F Hayes; Eric P Winer; Lynn Dressler Journal: Breast Cancer Res Date: 2006 Impact factor: 6.466
Authors: Marium Husain; Timiya S Nolan; Kevin Foy; Raquel Reinbolt; Cassandra Grenade; Maryam Lustberg Journal: Support Care Cancer Date: 2018-11-20 Impact factor: 3.603
Authors: V S Blinder; M M Murphy; L T Vahdat; H T Gold; I de Melo-Martin; M K Hayes; R J Scheff; E Chuang; A Moore; M Mazumdar Journal: J Community Health Date: 2012-08
Authors: Sunita Sharma; Amy Murphy; Judie Howrylak; Blanca Himes; Michael H Cho; Jen-Hwa Chu; Gary M Hunninghake; Anne Fuhlbrigge; Barbara Klanderman; John Ziniti; Jody Senter-Sylvia; Andy Liu; Stanley J Szefler; Robert Strunk; Mario Castro; Nadia N Hansel; Gregory B Diette; Becky M Vonakis; N Franklin Adkinson; Vincent J Carey; Benjamin A Raby Journal: Genet Epidemiol Date: 2011-02 Impact factor: 2.135
Authors: Jasgit C Sachdev; Saira Ahmed; Muhammad M Mirza; Aamer Farooq; Lori Kronish; Mohammad Jahanzeb Journal: Breast Cancer (Auckl) Date: 2010-05-07
Authors: Christine Leopold; Anita K Wagner; Fang Zhang; Christine Y Lu; Craig Earle; Larissa Nekhlyudov; Dennis Ross-Degnan; J Frank Wharam Journal: Breast Cancer Res Treat Date: 2016-06-24 Impact factor: 4.872
Authors: Sharon A Glynn; Brenda J Boersma; Tiffany M Howe; Hege Edvardsen; Stephanie B Geisler; Julie E Goodman; Lisa A Ridnour; Per E Lønning; Anne-Lise Børresen-Dale; Bjorn Naume; Vessela N Kristensen; Stephen J Chanock; David A Wink; Stefan Ambs Journal: Clin Cancer Res Date: 2009-06-09 Impact factor: 12.531